Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Liver Transpl. 2024 Oct 1;30(10):991-1001. doi: 10.1097/LVT.0000000000000418. Epub 2024 Jun 21.
Physical frailty is a critical determinant of mortality in patients with cirrhosis and can be objectively measured using the Liver Frailty Index (LFI), which is potentially modifiable. We aimed to identify LFI cut-points associated with waitlist mortality. Ambulatory adults with cirrhosis without HCC awaiting liver transplantation from 9 centers from 2012 to 2021 for ≥3 months with ≥2 pre-liver transplantation LFI assessments were included. The primary explanatory variable was the change in LFI from first to second assessments per 3 months (∆LFI); we evaluated clinically relevant ∆LFI cut-points at 0.1, 0.2, 0.3, and 0.5. The primary outcome was waitlist mortality (death or delisting for being too sick), with transplant considered as a competing event. Among 1029 patients, the median (IQR) age was 58 (51-63) years; 42% were female; and the median lab Model for End-Stage Liver Disease-Sodium at first assessment was 18 (15-22). For each 0.1 improvement in ∆LFI, the risk of overall mortality decreased by 6% (cause-specific hazard ratio: 0.94, 95% CI: 0.92-0.97, p < 0.001). ∆LFI was associated with waitlist mortality at cut-points as low as 0.1 (cause-specific hazard ratio: 0.63, 95% CI: 0.46-0.87) and 0.2 (HR: 0.61, 95% CI: 0.42-0.87). An improvement in LFI per 3 months as small as 0.1 in the pre-liver transplantation period is associated with a clinically meaningful reduction in waitlist mortality. These data provide estimates of the reduction in mortality risk associated with improvements in LFI that can be used to assess the effectiveness of interventions targeting physical frailty in patients with cirrhosis.
身体虚弱是肝硬化患者死亡的关键决定因素,可以使用肝脏虚弱指数(LFI)客观测量,而且该指数是可以改变的。我们的目的是确定与等待移植名单死亡率相关的 LFI 切点。本研究纳入了 2012 年至 2021 年期间来自 9 个中心的、患有肝硬化且没有 HCC、等待肝移植时间超过 3 个月、至少有 2 次肝移植前 LFI 评估的非卧床成年人。主要解释变量为每 3 个月的第一次和第二次 LFI 评估之间的 LFI 变化(∆LFI);我们评估了临床相关的 ∆LFI 切点为 0.1、0.2、0.3 和 0.5。主要结果是等待移植名单上的死亡率(死亡或因病情过重而被取消移植资格),将移植视为竞争事件。在 1029 名患者中,中位(IQR)年龄为 58(51-63)岁;42%为女性;第一次评估时的实验室模型终末期肝病评分钠中位数为 18(15-22)。∆LFI 每增加 0.1,总死亡率的风险降低 6%(特定原因的危险比:0.94,95%CI:0.92-0.97,p < 0.001)。∆LFI 与死亡率的相关性在低至 0.1(特定原因的危险比:0.63,95%CI:0.46-0.87)和 0.2(HR:0.61,95%CI:0.42-0.87)的切点处相关。肝移植前每 3 个月 LFI 增加 0.1 与等待移植名单死亡率的显著降低相关。这些数据提供了与 LFI 改善相关的死亡率降低风险的估计,可用于评估针对肝硬化患者身体虚弱的干预措施的效果。